To this aim, we pretreated the four representative MPM cell lines (NCI-H2373, HP1, SPC-212, MSTO-211H) with arachidonyl-trifluoromethyl ketone [32], or with AVX-001 [33], both specific phospholipase A2 (cPLA2) inhibitors (Fig. 3C), the latter one in clinical use for psoriasis [34]. Here, PLA2G4A is linked to psoriasis.